Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson's disease
Researchers conducted a double-blind, randomised trial on more than 190 people suffering from Parkinson's disease.
Half of the participants received a weekly injection of two milligrams of the drug exenatide, which is a GLP-1 receptor agonist similar to medicines such as Ozempic or Wegovy.
The other half of the study participants received a placebo.
At the end of the trial, the researchers found no improvement in symptoms or brain imaging after 96 weeks of treatment, according to the study's findings published in The Lancet.
'The results of this trial have been eagerly anticipated, and the negative results will be a major disappointment to patients affected by Parkinson's disease and the Parkinson's disease research community,' Thomas Foltynie, a professor at University College London (UCL) and the study's lead author, said in a statement.
'It is not yet clear whether there may be a subgroup of people with Parkinson's disease who may get benefit from the use of exenatide,' he added.
He said that there will be more research to see if for example, people with 'pre-diabetes' might 'predict a better response to exenatide'.
Previous small trials have suggested that these medications could have potential benefits for people with Parkinson's disease.
Exenatide, marketed as Byetta, is mainly used to help people with Type 2 diabetes manage blood sugar levels, according to the European Medicines Agency.
These drugs work by enhancing insulin secretion and slowing digestion, which can reduce food intake and appetite.
Related
Popular drugs Ozempic, Wegovy found to cut heart disease and keep weight off for up to 4 years
Popular weight-loss drugs like Ozempic could treat opioid overdose and alcohol intoxication
Exenatide was the first GLP-1 drug approved by US regulators for treating diabetes in 2005. This class of drugs is now also used in some cases to treat obesity.
Trials have also looked at their potential to help patients with a wide range of conditions ranging from heart disease to opioid overdose and alcohol intoxication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
15-Year Long Stagnant Life Expectancy Trend In U.S. Continues
Life expectancy in the U.S. has been stagnant for 15 years. Multiple factors are to blame. getty Approximately 525,000 more deaths occurred in the United States in 2023 than would have been expected based on pre-2010 mortality trends. The large number of excess deaths can be attributed to many different diseases and conditions. Cardiovascular disease continues to top the causes of mortality, along with cancer. But medical errors, overdose fatalities, gun deaths, infant mortality and other causes all contribute to the troublesome trend. U.S. life expectancy has been largely stagnant for 15 years. The Centers for Disease Control and Prevention report on mortality in the U.S. shows that life expectancy at birth rose from 77.5 in 2022 to 78.4 in 2023. While the bump between 2022 and 2023 is good news and signals a continued bounce-back from significant declines in 2020 and 2021 owing to the COVID-19 pandemic, the figure is still below the 2010 level. And preliminary data suggest that compared to 2023 the improvement in life expectancy in 2024 could be much smaller, as the rebound appears to be losing steam. Over the next 25 years, life expectancy in the U.S. is projected to rise by approximately two years—far less than in other wealthy, industrialized nations, according to a study published in The Lancet and carried out by the Institute for Health Metrics and Evaluation. Specifically, U.S. life expectancy is forecast to increase from its 2023 level to 80·4 years in 2050. This modest gain will see the U.S. fall from 49th to 66th globally in life expectancy rankings. Life expectancy is an estimate of the average number of years a baby born in a given year might expect to live, given death rates at that time. It's considered a fundamental measure of a population's health. A newly released report by the Bloomberg American Health Initiative highlights some of the reasons why the sharp divergence between U.S. life expectancy and its peers will likely persist, including the relatively elevated incidence and prevalence of cardiovascular disease, obesity and diabetes, as well as high levels of drug overdoses, gun deaths, motor vehicle fatalities and infant and maternal mortality. These help to explain, for example, the 2.7-year gap in life expectancy between the U.S. and the United Kingdom. Other rich countries such as Japan, Korea, Portugal, the U.K. and Italy all currently enjoy a life expectancy of 80 years or more. And since 1980 the gap between the U.S. and its peers has widened substantially. A Journal of the American Medical Association study analyzing 170 health indicators for U.S. children from 2007–2023 paints an especially sobering picture for the nation's youth, as infant mortality is 1.8 times higher than other wealthy nations; firearms are a top cause of death; obesity, anxiety and depression are rising relative to peers. What has alarmed policymakers for decades is that the U.S. experiences comparatively subpar life expectancy despite spending considerably more on healthcare. In fact, the U.S. spends much more in absolute and per capita terms on healthcare than any other nation. Health and Human Services Secretary Robert F. Kennedy Jr. has spoken of a 'life expectancy crisis.' He points to chronic diseases as the main underlying problem. Specifically, he cites rising rates of obesity, diabetes and cancer, as well as autoimmune diseases, neurodevelopmental disorders, Alzheimer's, asthma and addiction. Kennedy blames poor diets and environmental toxins for the increase in chronic disease rates. It follows that he's focused on chronic disease prevention, with a special emphasis on nutrition and removing certain ingredients and additives from food and beverages. Diet has invariably been integral to the Make America Healthy Again movement that Kennedy began. MAHA is taking aim at artificial dyes, pesticides, and additives, while trying to shift American eating habits away from ultra-processed foods. Kennedy is planning a public awareness campaign on the links between ultra-processed food and diabetes. While Kennedy's ideas to improve nutrition have some backing in the public health community, they could clash with the vested interests of the food industry as well as other Trump administration policies. Kennedy and his allies say Europe's food regulations help explain its lower rates of chronic disease, but experts suggest they may be overlooking European policies with possibly more impact, such as universal access to healthcare, a lower poverty rate and less exposure to air pollution. Additionally, Kennedy may be ignoring certain areas which could ameliorate the stagnant life expectancy trend, such as policies targeting gun violence, infant and maternal mortality, motor vehicle fatalities and medical errors. Equally important are courses of action that would tackle 'diseases of despair,' such as suicide, alcoholism and illicit drug use. Kennedy says he's determined to 'prevent addiction,' but steep budget cuts passed by Congress may undermine his efforts at curbing substance abuse disorders. Public health in America faces enormous challenges, not least of which are shrinking budgets at the federal and state levels. Experts across the political divide agree that addressing stagnant life expectancy requires sustained government funding of a wide range of initiatives that affect public health.
Business Insider
6 hours ago
- Business Insider
Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect
Hims & Hers Health (HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS stock has rallied 171% year-to-date, as investors are confident about the prospects of the health and wellness company, including its continued international expansion. However, Wall Street is cautious on Hims & Hers Health stock due to certain concerns, including the recent fallout with Novo Nordisk (NVO) over the alleged illegal sale of compounded versions of the weight loss drug Wegovy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wall Street expects HIMS to report earnings per share (EPS) of $0.15, reflecting a 150% year-over-year growth. Sales are expected to grow by about 75% to $551.67 million. TD Cowen Analyst's Views Ahead of Hims & Hers Health's Q2 Earnings Heading into Q2 results, TD Cowen analyst Jonna Kim reiterated a Hold rating on HIMS stock but raised the price target to $43 from $38. The 4-star analyst expects the company to deliver an EPS beat. Kim expects Q2 sales growth to come above the Street's estimate. However, Kim noted that the latest data points indicate a deceleration in trends, which could lead to management maintaining the full-year outlook. The analyst remains neutral on HIMS stock as comparisons get tougher in the second half of 2025, with uncertainty around compounded GLP-1s. Nonetheless, Kim believes that international growth could be meaningful to HIMS' sales starting in Fiscal 2026. Kim noted the rally in HIMS stock and stated that he sees a lack of substantial upside in the second half of 2025, as the company 'laps outsized growth' from last year. AI Analyst Is Bullish on HIMS Stock Ahead of Q2 Print Interestingly, TipRanks' AI stock analyst has assigned an Outperform rating to HIMS stock with a price target of $73, indicating 16.7% downside risk. Based on TipRanks' AI analysis, HIMS stock reflects significant strength in financial performance and strategic growth plans, supported by favorable earnings call insights. However, high valuation and technical indicators suggest caution, especially given potential overbought conditions and margin pressures. Options Traders Anticipate Major Move on Hims & Hers Health's Q2 Earnings Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting about a 17.3% move in either direction in HIMS stock in reaction to Q2 results. Is HIMS Stock a Good Buy? Currently, Wall Street has a Hold consensus rating on Hims & Hers Health stock based on one Buy, seven Holds, and two Sell recommendations. The average HIMS stock price target of $42.33 indicates 32.3% downside risk from current levels.
Epoch Times
11 hours ago
- Epoch Times
Taiwanese Doctor Expresses Concern Over China's Organ Industry
A Taiwanese doctor who is part of a medical ethics nonprofit has expressed concerns about China's organ industry, especially regarding children. Huang Shiwei, vice chairman of the medical ethics nonprofit Taiwan International Organ Transplant Care Association, told NTD's Health 1+1 program that he was troubled by an alleged order that a hospital gave medical student Luo Shuaiyu. The medical student, Luo Shuaiyu, specialized in kidney transplantation at the Second Xiangya Hospital of Central South University. Authorities said Luo fell to his death from a building in May 2024, just weeks before his graduation. According to audio recordings released by his parents after his death, Luo had been asked to locate 12 child donors aged 3 to 9, ostensibly for medical purposes. Huang said this is concerning given China's record of forced organ harvesting. 'They asked [Luo] to find child donors. Where was he supposed to look?' Huang said. Pediatric Organs On May 21, 2024, Fudan University Medical College in Shanghai established a pediatric organ transplant center. According to the university, Li Qian, the Chinese Communist Party (CCP) secretary at the pediatric hospital, said that 'in just over a year, [pediatric organ transplants] have exceeded 100 cases.' State media outlet Sina reported that the hospital has performed highly complex surgeries, including kidney transplants from donors weighing less than 5 kg (11 pounds), indicating that newborns are among the donors. In 2017, the First Affiliated Hospital of Sun Yat-sen University in Guangzhou reported that 90 percent of pediatric kidney donors were allocated to adult patients. A 2023 study by doctors from Shanghai Jiao Tong University's Renji Hospital, published in the American Journal of Transplantation, detailed two cases of kidney transplants from newborns born at 29 weeks and 29 weeks, 5 days to adult women aged 34 and 25 with end-stage kidney disease. The kidneys were harvested on the second and third days after birth, prompting ethical scrutiny. Shabih Manzar, associate professor of clinical pediatrics at Louisiana State University, questioned the procedure in the same journal, noting that one of the 29-week preterm infants had no apparent life-threatening conditions, casting doubt on the decision to withdraw life-sustaining treatment. Huang noted the high survival rates of 29-week preterm infants with modern medical technology. 'Whether it's the parents or the medical system, everyone would typically do everything possible to save these preterm newborns,' he said. 'No one would give up and simply designate them as organ donors. Yet, we see that they are using 29-week preterm infants as organ donors.' China's Organ Harvesting Industry China began using organs from executed prisoners following a 1984 regulation allowing the practice. After 1999, when the regime began persecuting the spiritual group Falun Gong, China's organ transplant industry exponentially increased. Huang noted that when former CCP leader Jiang Zemin initiated the persecution campaign against Falun Gong, practitioners were branded as 'class enemies,' making them prime targets for forced organ harvesting. This period marked an unprecedented surge in organ transplants. According to data from the World Organization to Investigate the Persecution of Falun Gong, compiled from Chinese state media reports, only 135 liver transplants were recorded in China over more than two decades before 1999, averaging five to six cases annually. From 1999 to 2006, liver transplants skyrocketed to 14,085 cases over the eight-year period, averaging more than 1,700 cases per year—a 180-fold increase. 'Organ transplantation in China suddenly became a massive industry,' Huang said. 'With countless patients in China and worldwide needing organs, there are enormous commercial interests at play.' In March 2006, a whistleblower using the pseudonym Annie, a former employee of Sujiatun Thrombosis Hospital in Shenyang, Liaoning Province, revealed to The Epoch Times the CCP's horrific practice of forced organ harvesting from Falun Gong practitioners. This exposure had a significant impact on China's organ transplant industry. According to the China Liver Transplant Registry, cited by state media People's Daily, liver transplants peaked at 2,970 cases in 2005 and 2,781 in 2006 but fell by roughly one-third to 1,822 cases in 2007. Huang attributed this decline to the 2006 revelations. 'The reason for the decrease in organ transplants in China in 2007 was the exposure of the CCP's forced organ harvesting from Falun Gong practitioners,' Huang said. 'As relatives relentlessly searched for family members detained for practicing Falun Gong, it became increasingly difficult for the CCP's public security and medical personnel to continue using Falun Gong practitioners' organs on such a large scale.' He said the drop in transplant numbers underscores the international scrutiny and domestic pressure that began to disrupt the CCP's organ harvesting operations. Concerns 'Forced organ harvesting in China appears to be targeting specific ethnic, linguistic, or religious minorities held in detention, often without being explained the reasons for arrest or given arrest warrants, at different locations,' according to a 2021 joint statement from the U.N. Office of the High Commissioner for Human Rights. Huang said: 'In most countries, organ donors tend to be older, 50, 60, or even 70 years old. But in China, the organ transplant industry operates differently. When organs are supplied to wealthy individuals, they naturally demand those from younger people.' Huang said he believes in China there is now an increasing focus on obtaining organs from young individuals, including children. A surge in mysterious disappearances of adolescents across multiple Chinese provinces in recent years has fueled public suspicion of organ trafficking, especially because of China's extensive surveillance infrastructure. In October 2022, Hu Xinyu, a first-year high school student in eastern China's Jiangxi Province, mysteriously disappeared from school. Various reports from insiders and overseas whistleblowers allege that the Hu case is linked to forced organ harvesting. In August 2023, 8-year-old Wang Sijun, who had a rare Rh-negative blood type, died unexpectedly while receiving treatment at Yunnan Red Cross Hospital. According to viral videos posted by her family on platforms such as Douyin, Wang was admitted for a routine examination while accompanying a relative, only to die in the nephrology ward. Her autopsy cited hemorrhagic shock as the cause of death, with traces of the anticoagulant enoxaparin sodium detected, leading her family to suspect blood extraction and organ theft. Although no definitive evidence confirms organ harvesting in the case, Huang noted that widespread allegations of hospitals engaging in such practices have created a climate of heightened anxiety. Documented cases, such as a fraudulent organ donation scandal in Anhui Province's Bengbu City, lend credence to these concerns. Between 2017 and 2018, six defendants, including four doctors, were convicted of deceiving families and illegally harvesting organs from at least 11 patients. 'China's organ transplant industry, driven by the Communist Party's ideology, has evolved into a vast commercial enterprise,' Huang said. 'These cases show it has become an unregulated beast, with rampant, unchecked organ harvesting.'
